$MRNS
MARINUS PHARMACEUTICALS, INC.

2024 Q1 Form 10-K Financial Statement

#000155837024002479 Filed on March 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $7.679M $7.190M $30.99M
YoY Change -26.02% 0.39% 21.63%
Cost Of Revenue $756.0K $887.0K $1.934M
YoY Change 266.99% 203.77% 28.16%
Gross Profit $6.923M $6.303M $29.06M
YoY Change -31.95% -8.25% 21.22%
Gross Profit Margin 90.15% 87.66% 93.76%
Selling, General & Admin $18.63M $15.36M $61.15M
YoY Change 22.51% 4.78% 7.58%
% of Gross Profit 269.05% 243.66% 210.47%
Research & Development $24.12M $26.38M $99.39M
YoY Change -13.66% 23.14% 24.37%
% of Gross Profit 348.37% 418.56% 342.07%
Depreciation & Amortization $131.0K $125.0K $551.0K
YoY Change -16.56% 52.44% 31.82%
% of Gross Profit 1.89% 1.98% 1.9%
Operating Expenses $42.74M $41.74M $160.5M
YoY Change -0.91% 15.68% 17.39%
Operating Profit -$35.82M -$35.44M -$131.5M
YoY Change 8.67% 21.31% 16.58%
Interest Expense $4.346M -$2.551M $16.90M
YoY Change 4.8% 31.09% 58.31%
% of Operating Profit
Other Income/Expense, Net $36.00K $219.0K $1.324M
YoY Change -2.7% -130.54% -149.11%
Pretax Income -$38.67M -$41.77M -$142.9M
YoY Change 11.34% 27.83% 770.17%
Income Tax $0.00 -$1.500M
% Of Pretax Income
Net Earnings -$38.70M -$41.77M -$141.4M
YoY Change 11.53% 22.94% 614.14%
Net Earnings / Revenue -503.97% -580.93% -456.29%
Basic Earnings Per Share -$0.68 -$2.63
Diluted Earnings Per Share -$0.68 -$0.74 -$2.63
COMMON SHARES
Basic Shares Outstanding 54.64M 54.57M 53.75M
Diluted Shares Outstanding 56.85M 53.75M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $113.3M $150.3M $150.3M
YoY Change -43.15% -37.52% -37.52%
Cash & Equivalents $104.3M $120.6M $120.6M
Short-Term Investments $9.000M $29.72M $29.72M
Other Short-Term Assets $8.727M $8.746M $8.746M
YoY Change -3.72% 61.9% 61.9%
Inventory $5.783M $2.413M $2.413M
Prepaid Expenses
Receivables $3.513M $3.799M $3.799M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $131.3M $165.2M $165.2M
YoY Change -40.33% -34.52% -34.52%
LONG-TERM ASSETS
Property, Plant & Equipment $3.735M $3.843M $4.843M
YoY Change -7.48% -9.28% -12.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.339M $1.819M $819.0K
YoY Change -16.01% -37.36% -48.94%
Total Long-Term Assets $6.074M $5.662M $5.662M
YoY Change -10.96% -20.7% -20.7%
TOTAL ASSETS
Total Short-Term Assets $131.3M $165.2M $165.2M
Total Long-Term Assets $6.074M $5.662M $5.662M
Total Assets $137.4M $170.9M $170.9M
YoY Change -39.44% -34.14% -34.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.125M $4.003M $4.003M
YoY Change 37.15% -10.27% -10.27%
Accrued Expenses $18.72M $22.86M $22.86M
YoY Change 19.04% 17.01% 17.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $15.40M $11.55M $11.55M
YoY Change
Total Short-Term Liabilities $42.76M $40.62M $40.62M
YoY Change 98.75% 62.39% 62.39%
LONG-TERM LIABILITIES
Long-Term Debt $58.07M $61.42M $61.42M
YoY Change -18.78% -13.51% -13.51%
Other Long-Term Liabilities $52.95M $52.10M $52.10M
YoY Change 8.69% 9.72% 9.72%
Total Long-Term Liabilities $111.0M $113.5M $113.5M
YoY Change -7.65% -4.2% -4.2%
TOTAL LIABILITIES
Total Short-Term Liabilities $42.76M $40.62M $40.62M
Total Long-Term Liabilities $111.0M $113.5M $113.5M
Total Liabilities $153.8M $154.1M $154.1M
YoY Change 8.5% 7.4% 7.4%
SHAREHOLDERS EQUITY
Retained Earnings -$610.6M -$571.9M
YoY Change 31.23% 32.85%
Common Stock $55.00K $55.00K
YoY Change 10.0% 10.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$16.43M $16.77M $16.77M
YoY Change
Total Liabilities & Shareholders Equity $137.4M $170.9M $170.9M
YoY Change -39.44% -34.14% -34.14%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$38.70M -$41.77M -$141.4M
YoY Change 11.53% 22.94% 614.14%
Depreciation, Depletion And Amortization $131.0K $125.0K $551.0K
YoY Change -16.56% 52.44% 31.82%
Cash From Operating Activities -$37.46M -$26.99M -$118.0M
YoY Change -9.68% 23.17% 4.53%
INVESTING ACTIVITIES
Capital Expenditures $34.00K $119.0K
YoY Change -63.04% -93.29%
Acquisitions
YoY Change
Other Investing Activities $20.89M $6.500M -$28.49M
YoY Change -140.17% 3701.17% -126.49%
Cash From Investing Activities $20.89M $6.466M -$28.61M
YoY Change -140.17% 8084.81% -127.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 257.0K 661.0K 26.63M
YoY Change -247.7% -99.3% -78.65%
NET CHANGE
Cash From Operating Activities -37.46M -26.99M -118.0M
Cash From Investing Activities 20.89M 6.466M -28.61M
Cash From Financing Activities 257.0K 661.0K 26.63M
Net Change In Cash -16.32M -19.87M -120.0M
YoY Change -82.57% -127.48% -202.0%
FREE CASH FLOW
Cash From Operating Activities -$37.46M -$26.99M -$118.0M
Capital Expenditures $34.00K $119.0K
Free Cash Flow -$27.03M -$118.1M
YoY Change 22.81% 3.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity File Number
EntityFileNumber
001-36576
CY2023 dei Entity Registrant Name
EntityRegistrantName
Marinus Pharmaceuticals, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0198082
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53746518
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39072599
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001267813
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesNoncurrent
CY2022Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesNoncurrent
CY2023Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesNoncurrent
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.63
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesNoncurrent
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
5 Radnor Corporate Center, Suite 500
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
100 Matsonford Road
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Radnor
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19087
CY2023 dei City Area Code
CityAreaCode
484
CY2023 dei Local Phone Number
LocalPhoneNumber
801-4670
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023 dei Trading Symbol
TradingSymbol
MRNS
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
545158729
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54642580
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120572000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
240551000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
29716000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3799000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6348000
CY2023Q4 us-gaap Inventory Net
InventoryNet
2413000
CY2022Q4 us-gaap Inventory Net
InventoryNet
77000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8746000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5402000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
165246000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
252378000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3843000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4236000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1819000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2904000
CY2023Q4 us-gaap Assets
Assets
170908000
CY2022Q4 us-gaap Assets
Assets
259518000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4003000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4461000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
11551000
CY2023Q4 mrns Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
2211000
CY2022Q4 mrns Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
1020000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22859000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19536000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40624000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25017000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
61423000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
71018000
CY2023Q4 mrns Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent
RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent
33766000
CY2022Q4 mrns Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent
RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent
29857000
CY2023Q4 mrns Contract With Customer Contract Liability Net Of Contract Asset
ContractWithCustomerContractLiabilityNetOfContractAsset
17545000
CY2022Q4 mrns Contract With Customer Contract Liability Net Of Contract Asset
ContractWithCustomerContractLiabilityNetOfContractAsset
16285000
CY2023Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
785000
CY2022Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
1341000
CY2023Q4 us-gaap Liabilities
Liabilities
154143000
CY2022Q4 us-gaap Liabilities
Liabilities
143518000
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
4043000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54585428
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54578121
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49650074
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49642767
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
55000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
50000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
588656000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
542428000
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
7307
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
7307
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-20000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-571926000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-430521000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
16765000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
116000000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
170908000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
259518000
CY2023 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
11374000
CY2022 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
6935000
CY2023 us-gaap Revenues
Revenues
30989000
CY2022 us-gaap Revenues
Revenues
25478000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
99388000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
79912000
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
61152000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
56845000
CY2022 mrns Cost Of License Fees
CostOfLicenseFees
1169000
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
162474000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
138266000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-131485000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-112788000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
8113000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
2354000
CY2023 us-gaap Interest Expense
InterestExpense
16895000
CY2022 us-gaap Interest Expense
InterestExpense
10672000
CY2023 mrns Gain Loss On Sale Of Priority Review Voucher Net
GainLossOnSaleOfPriorityReviewVoucherNet
-4000000
CY2022 mrns Gain Loss On Sale Of Priority Review Voucher Net
GainLossOnSaleOfPriorityReviewVoucherNet
107375000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1324000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2696000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-142943000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16427000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1538000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3389000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-141405000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19816000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.63
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.63
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53746518
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53746518
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39072599
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39072599
CY2023 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-20000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-141425000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19816000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
53486000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14890000
CY2022 mrns Issuance Of Common Stock And Prefunded Warrants
IssuanceOfCommonStockAndPrefundedWarrants
64477000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1794000
CY2022 mrns Stock Issued During Period Value Related To License Agreement
StockIssuedDuringPeriodValueRelatedToLicenseAgreement
1169000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-19816000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
116000000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15563000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
804000
CY2023Q4 us-gaap Share Price
SharePrice
7.17
CY2023 mrns Stock Issuance Costs
StockIssuanceCosts
529000
CY2023 mrns Stock Issued During Period Value Equity Distribution Agreement
StockIssuedDuringPeriodValueEquityDistributionAgreement
25823000
CY2023 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-20000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-141405000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
16765000
CY2023 us-gaap Profit Loss
ProfitLoss
-141405000
CY2022 us-gaap Profit Loss
ProfitLoss
-19816000
CY2022 mrns Gain On Sale Of Priority Review Voucher Net
GainOnSaleOfPriorityReviewVoucherNet
107375000
CY2023 us-gaap Depreciation
Depreciation
551000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
29736000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
169000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
189000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
29716000
CY2022 us-gaap Depreciation
Depreciation
418000
CY2023 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2248000
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1663000
CY2023 mrns Accretion Of Revenue Interest Financing Debt
AccretionOfRevenueInterestFinancingDebt
4806000
CY2022 mrns Accretion Of Revenue Interest Financing Debt
AccretionOfRevenueInterestFinancingDebt
956000
CY2023 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
1241000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
15563000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
14890000
CY2023 mrns Increase Decrease Amortization Of Net Contract Asset Liability
IncreaseDecreaseAmortizationOfNetContractAssetLiability
1353000
CY2022 mrns Increase Decrease Amortization Of Net Contract Asset Liability
IncreaseDecreaseAmortizationOfNetContractAssetLiability
1052000
CY2023 mrns Non Cash Operating Lease Expense Operating Activities
NonCashOperatingLeaseExpenseOperatingActivities
187000
CY2022 mrns Non Cash Operating Lease Expense Operating Activities
NonCashOperatingLeaseExpenseOperatingActivities
251000
CY2023 mrns Interest Expense Income On Lease Liabilities
InterestExpenseIncomeOnLeaseLiabilities
413000
CY2022 mrns Interest Expense Income On Lease Liabilities
InterestExpenseIncomeOnLeaseLiabilities
344000
CY2023 mrns Fixed Assets Written Off
FixedAssetsWrittenOff
61000
CY2022 mrns Fixed Assets Written Off
FixedAssetsWrittenOff
828000
CY2022 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1169000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-930000
CY2022 mrns Increase Decrease In Contract With Customer Refund Liability
IncreaseDecreaseInContractWithCustomerRefundLiability
-22163000
CY2023 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-2613000
CY2022 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-17894000
CY2023 mrns Increase Decrease In Prepaid Expense And Other Assets Noncurrent Assets Inventory And Accounts Receivable
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsNoncurrentAssetsInventoryAndAccountsReceivable
2552000
CY2022 mrns Increase Decrease In Prepaid Expense And Other Assets Noncurrent Assets Inventory And Accounts Receivable
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsNoncurrentAssetsInventoryAndAccountsReceivable
5577000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2108000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3754000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-118001000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-112886000
CY2022 mrns Proceeds From Sale Of Priority Review Voucher
ProceedsFromSaleOfPriorityReviewVoucher
107375000
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
9000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
171000
CY2023 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
23500000
CY2023 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
51995000
CY2023 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
119000
CY2022 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
1774000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-28605000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
105772000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
804000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1794000
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
28588000
CY2022 mrns Proceeds From Revenue Interest Financing Agreement Net Of Issuance Costs
ProceedsFromRevenueInterestFinancingAgreementNetOfIssuanceCosts
29921000
CY2023 mrns Proceeds From Equity Offerings Net
ProceedsFromEquityOfferingsNet
25823000
CY2022 mrns Proceeds From Equity Offerings Net
ProceedsFromEquityOfferingsNet
64477000
CY2022 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-42000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26627000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
124738000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-119979000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
117624000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
240551000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1300000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122927000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
120572000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
240551000
CY2023 mrns Increase In Right Of Use Asset And Liability
IncreaseInRightOfUseAssetAndLiability
66000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
22000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
8697000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
7892000
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
903000
CY2022 mrns Property And Equipment In Deposits Placed In Service
PropertyAndEquipmentInDepositsPlacedInService
1664000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-141400000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-571900000
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
150300000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates.</p>
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023 mrns Number Of Customers
NumberOfCustomers
3
CY2023 mrns Trade Receivable Payment Term
TradeReceivablePaymentTerm
P30D
CY2023 mrns Number Of Customers
NumberOfCustomers
3
CY2023Q4 mrns Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
4700000
CY2022Q4 mrns Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
5700000
CY2023Q4 mrns Prepaid Clinical Expenses
PrepaidClinicalExpenses
5200000
CY2022Q4 mrns Prepaid Clinical Expenses
PrepaidClinicalExpenses
3900000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-141405000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19816000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53746518
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39072599
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.63
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8436875
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7262195
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
29736000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
169000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
189000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
29716000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5743000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5690000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1900000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1454000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3843000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4236000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2022Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group
AssetsHeldForSaleNotPartOfDisposalGroup
700000
CY2023Q4 mrns Lease Liability Short Term
LeaseLiabilityShortTerm
774000
CY2022Q4 mrns Lease Liability Short Term
LeaseLiabilityShortTerm
637000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
501000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
371000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22859000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19536000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1000000.0
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5743000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5690000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1900000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1454000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3843000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4236000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2022Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group
AssetsHeldForSaleNotPartOfDisposalGroup
700000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7746000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7061000
CY2023Q4 mrns Clinical Trials And Drug Development Current
ClinicalTrialsAndDrugDevelopmentCurrent
4701000
CY2022Q4 mrns Clinical Trials And Drug Development Current
ClinicalTrialsAndDrugDevelopmentCurrent
5725000
CY2023Q4 mrns Accrued License Agreement Payment
AccruedLicenseAgreementPayment
4000000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1236000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1417000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2445000
CY2023Q4 mrns Selling And Commercial Liabilities Current
SellingAndCommercialLiabilitiesCurrent
3901000
CY2022Q4 mrns Selling And Commercial Liabilities Current
SellingAndCommercialLiabilitiesCurrent
1880000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7746000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7061000
CY2023Q4 mrns Clinical Trials And Drug Development Current
ClinicalTrialsAndDrugDevelopmentCurrent
4701000
CY2022Q4 mrns Clinical Trials And Drug Development Current
ClinicalTrialsAndDrugDevelopmentCurrent
5725000
CY2023Q4 mrns Accrued License Agreement Payment
AccruedLicenseAgreementPayment
4000000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1236000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1417000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2445000
CY2023Q4 mrns Selling And Commercial Liabilities Current
SellingAndCommercialLiabilitiesCurrent
3901000
CY2022Q4 mrns Selling And Commercial Liabilities Current
SellingAndCommercialLiabilitiesCurrent
1880000
CY2023Q4 mrns Lease Liability Short Term
LeaseLiabilityShortTerm
774000
CY2022Q4 mrns Lease Liability Short Term
LeaseLiabilityShortTerm
637000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
501000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
371000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22859000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19536000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1000000.0
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1300000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1400000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2000000.0
CY2022 us-gaap Lease Cost
LeaseCost
600000
CY2023 us-gaap Lease Cost
LeaseCost
600000
CY2022 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2023 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
889000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
662000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1551000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
144000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2000000.0
CY2022 us-gaap Lease Cost
LeaseCost
600000
CY2023 us-gaap Lease Cost
LeaseCost
600000
CY2022 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2023 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
889000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
662000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1551000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
144000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1407000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
774000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
633000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1407000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15563000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14890000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
15600000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
6400000
CY2023 mrns Revenue Interest Financing Agreement Estimated Effective Annual Interest Rate
RevenueInterestFinancingAgreementEstimatedEffectiveAnnualInterestRate
0.18
CY2022 mrns Revenue Interest Financing Agreement Estimated Effective Annual Interest Rate
RevenueInterestFinancingAgreementEstimatedEffectiveAnnualInterestRate
0.19
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1407000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
774000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
633000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1407000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15563000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14890000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
15600000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
6400000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
21953000
CY2022 mrns Maximum Percentage Of Beneficial Ownership For Exercise Of Pre Funded Warrants
MaximumPercentageOfBeneficialOwnershipForExerciseOfPreFundedWarrants
0.0999
CY2022 mrns Maximum Percentage Increase Or Decrease Of Beneficial Ownership For Exercise Of Pre Funded Warrants
MaximumPercentageIncreaseOrDecreaseOfBeneficialOwnershipForExerciseOfPreFundedWarrants
0.1999
CY2023 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3700000
CY2023 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
25800000
CY2022 mrns Stock Issued During Period Shares Equity Distribution Agreement
StockIssuedDuringPeriodSharesEquityDistributionAgreement
0
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
75000000.0
CY2023Q4 mrns Debt Instrument Minimum Liquidity Covenant
DebtInstrumentMinimumLiquidityCovenant
15000000.0
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
21953000
CY2022 mrns Maximum Percentage Of Beneficial Ownership For Exercise Of Pre Funded Warrants
MaximumPercentageOfBeneficialOwnershipForExerciseOfPreFundedWarrants
0.0999
CY2022 mrns Maximum Percentage Increase Or Decrease Of Beneficial Ownership For Exercise Of Pre Funded Warrants
MaximumPercentageIncreaseOrDecreaseOfBeneficialOwnershipForExerciseOfPreFundedWarrants
0.1999
CY2023 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3700000
CY2023 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
25800000
CY2022 mrns Stock Issued During Period Shares Equity Distribution Agreement
StockIssuedDuringPeriodSharesEquityDistributionAgreement
0
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
75000000.0
CY2023Q4 mrns Debt Instrument Minimum Liquidity Covenant
DebtInstrumentMinimumLiquidityCovenant
15000000.0
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
75000000
CY2023Q4 mrns Contractual Term Loan Exit Fees
ContractualTermLoanExitFees
2003000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
4029000
CY2023Q4 us-gaap Notes Payable
NotesPayable
72974000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
11551000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
61423000
CY2023Q4 us-gaap Notes Payable
NotesPayable
72974000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
11250000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
15000000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
48750000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
75000000
CY2023 mrns Revenue Interest Financing Agreement Issuance Costs
RevenueInterestFinancingAgreementIssuanceCosts
2600000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
75000000
CY2023Q4 mrns Contractual Term Loan Exit Fees
ContractualTermLoanExitFees
2003000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
4029000
CY2023Q4 us-gaap Notes Payable
NotesPayable
72974000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
11551000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
61423000
CY2023Q4 us-gaap Notes Payable
NotesPayable
72974000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
11250000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
15000000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
48750000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
75000000
CY2023 mrns Revenue Interest Financing Agreement Issuance Costs
RevenueInterestFinancingAgreementIssuanceCosts
2600000
CY2023 mrns Revenue Interest Financing Agreement Estimated Effective Annual Interest Rate
RevenueInterestFinancingAgreementEstimatedEffectiveAnnualInterestRate
0.18
CY2022 mrns Revenue Interest Financing Agreement Estimated Effective Annual Interest Rate
RevenueInterestFinancingAgreementEstimatedEffectiveAnnualInterestRate
0.19
CY2022Q4 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
32500000
CY2022Q4 mrns Revenue Interest Financing Agreement Issuance Costs
RevenueInterestFinancingAgreementIssuanceCosts
2579000
CY2022Q4 mrns Revenue Interest Financing Agreement Non Cash Interest Income Expense
RevenueInterestFinancingAgreementNonCashInterestIncomeExpense
956000
CY2022Q4 mrns Revenue Interest Financing Agreement Amortization Of Debt Discount
RevenueInterestFinancingAgreementAmortizationOfDebtDiscount
42000
CY2022Q4 mrns Revenue Interest Financing Agreement Payments
RevenueInterestFinancingAgreementPayments
-42000
CY2022Q4 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
30877000
CY2023 mrns Revenue Interest Financing Agreement Non Cash Interest Income Expense
RevenueInterestFinancingAgreementNonCashInterestIncomeExpense
5950000
CY2023 mrns Revenue Interest Financing Agreement Amortization Of Debt Discount
RevenueInterestFinancingAgreementAmortizationOfDebtDiscount
294000
CY2022Q4 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
32500000
CY2022Q4 mrns Revenue Interest Financing Agreement Issuance Costs
RevenueInterestFinancingAgreementIssuanceCosts
2579000
CY2022Q4 mrns Revenue Interest Financing Agreement Non Cash Interest Income Expense
RevenueInterestFinancingAgreementNonCashInterestIncomeExpense
956000
CY2022Q4 mrns Revenue Interest Financing Agreement Amortization Of Debt Discount
RevenueInterestFinancingAgreementAmortizationOfDebtDiscount
42000
CY2022Q4 mrns Revenue Interest Financing Agreement Payments
RevenueInterestFinancingAgreementPayments
-42000
CY2022Q4 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
30877000
CY2023 mrns Revenue Interest Financing Agreement Non Cash Interest Income Expense
RevenueInterestFinancingAgreementNonCashInterestIncomeExpense
5950000
CY2023 mrns Revenue Interest Financing Agreement Amortization Of Debt Discount
RevenueInterestFinancingAgreementAmortizationOfDebtDiscount
294000
CY2023 mrns Revenue Interest Financing Agreement Payments
RevenueInterestFinancingAgreementPayments
-1144000
CY2023Q4 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
35977000
CY2023Q4 mrns Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
2211000
CY2023Q4 mrns Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent
RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent
33766000
CY2023Q4 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
35977000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
400000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2023 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.03
CY2023 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1100000
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1000000.0
CY2023 mrns Defined Contribution Plan Employer Contribution Vesting Period
DefinedContributionPlanEmployerContributionVestingPeriod
P4Y
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16427000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
72792000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
58056000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1754000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
124000
CY2023Q4 mrns Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
468000
CY2022Q4 mrns Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
454000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8741000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8091000
CY2023 mrns Revenue Interest Financing Agreement Payments
RevenueInterestFinancingAgreementPayments
-1144000
CY2023Q4 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
35977000
CY2023Q4 mrns Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
2211000
CY2023Q4 mrns Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent
RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent
33766000
CY2023Q4 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
35977000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
400000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2023 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.03
CY2023 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1100000
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1000000.0
CY2023 mrns Defined Contribution Plan Employer Contribution Vesting Period
DefinedContributionPlanEmployerContributionVestingPeriod
P4Y
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-1538000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2445000
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
944000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-1538000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3389000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1538000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3389000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-142943000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-16427000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-142943000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
39588000
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-1538000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2445000
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
944000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-1538000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3389000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1538000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3389000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-142943000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-16427000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-142943000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16427000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
72792000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
58056000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1754000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
124000
CY2023Q4 mrns Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
468000
CY2022Q4 mrns Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
454000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8741000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8091000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
39588000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
30627000
CY2023Q4 mrns Deferred Tax Asset Lease Liability
DeferredTaxAssetLeaseLiability
345000
CY2022Q4 mrns Deferred Tax Asset Lease Liability
DeferredTaxAssetLeaseLiability
440000
CY2023Q4 mrns Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
37643000
CY2022Q4 mrns Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
22382000
CY2023Q4 mrns Deferred Tax Assets Royalty Or Deferred Revenue
DeferredTaxAssetsRoyaltyOrDeferredRevenue
4298000
CY2022Q4 mrns Deferred Tax Assets Royalty Or Deferred Revenue
DeferredTaxAssetsRoyaltyOrDeferredRevenue
3781000
CY2023Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
74000
CY2022Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
94000
CY2023Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
2152000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
152000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
64000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
30627000
CY2023Q4 mrns Deferred Tax Asset Lease Liability
DeferredTaxAssetLeaseLiability
345000
CY2022Q4 mrns Deferred Tax Asset Lease Liability
DeferredTaxAssetLeaseLiability
440000
CY2023Q4 mrns Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
37643000
CY2022Q4 mrns Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
22382000
CY2023Q4 mrns Deferred Tax Assets Royalty Or Deferred Revenue
DeferredTaxAssetsRoyaltyOrDeferredRevenue
4298000
CY2022Q4 mrns Deferred Tax Assets Royalty Or Deferred Revenue
DeferredTaxAssetsRoyaltyOrDeferredRevenue
3781000
CY2023Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
74000
CY2023Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
2152000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
152000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
64000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
168007000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
124113000
CY2023Q4 mrns Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
237000
CY2022Q4 mrns Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
291000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
458000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
224000
CY2023Q4 us-gaap Deferred Tax Liabilities Tax Deferred Income
DeferredTaxLiabilitiesTaxDeferredIncome
209000
CY2022Q4 us-gaap Deferred Tax Liabilities Tax Deferred Income
DeferredTaxLiabilitiesTaxDeferredIncome
192000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
904000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
707000
CY2023Q4 mrns Deferred Tax Assets Liabilities Before Valuation Allowance
DeferredTaxAssetsLiabilitiesBeforeValuationAllowance
167103000
CY2022Q4 mrns Deferred Tax Assets Liabilities Before Valuation Allowance
DeferredTaxAssetsLiabilitiesBeforeValuationAllowance
123406000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
167103000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
123406000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
43700000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7700000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 mrns Liability For Uncertain Tax Positions
LiabilityForUncertainTaxPositions
0
CY2023Q4 mrns Liability For Uncertain Tax Positions
LiabilityForUncertainTaxPositions
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1500000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.004
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.026
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.041
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.090
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.063
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.881
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.025
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.595
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.057
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.306
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.470
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.018
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
168007000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
124113000
CY2023Q4 mrns Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
237000
CY2022Q4 mrns Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
291000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
458000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
224000
CY2023Q4 us-gaap Deferred Tax Liabilities Tax Deferred Income
DeferredTaxLiabilitiesTaxDeferredIncome
209000
CY2022Q4 us-gaap Deferred Tax Liabilities Tax Deferred Income
DeferredTaxLiabilitiesTaxDeferredIncome
192000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
904000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
707000
CY2023Q4 mrns Deferred Tax Assets Liabilities Before Valuation Allowance
DeferredTaxAssetsLiabilitiesBeforeValuationAllowance
167103000
CY2022Q4 mrns Deferred Tax Assets Liabilities Before Valuation Allowance
DeferredTaxAssetsLiabilitiesBeforeValuationAllowance
123406000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
167103000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
123406000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
43700000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7700000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 mrns Liability For Uncertain Tax Positions
LiabilityForUncertainTaxPositions
0
CY2023Q4 mrns Liability For Uncertain Tax Positions
LiabilityForUncertainTaxPositions
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1500000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.004
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.026
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.041
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.090
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.063
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.881
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.025
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.595
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.057
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.306
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.470
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.018
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.059
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.011
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.206
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.059
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.011
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.206

Files In Submission

Name View Source Status
mrns-20231231x10k_htm.xml Edgar Link completed
0001558370-24-002479-index-headers.html Edgar Link pending
0001558370-24-002479-index.html Edgar Link pending
0001558370-24-002479.txt Edgar Link pending
0001558370-24-002479-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mrns-20231231.xsd Edgar Link pending
mrns-20231231x10k.htm Edgar Link pending
mrns-20231231x10k001.jpg Edgar Link pending
mrns-20231231x10k004.jpg Edgar Link pending
mrns-20231231xex10d7.htm Edgar Link pending
mrns-20231231xex21.htm Edgar Link pending
mrns-20231231xex23d1.htm Edgar Link pending
mrns-20231231xex31d1.htm Edgar Link pending
mrns-20231231xex31d2.htm Edgar Link pending
mrns-20231231xex32d1.htm Edgar Link pending
mrns-20231231xex4d2.htm Edgar Link pending
mrns-20231231xex97.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mrns-20231231_cal.xml Edgar Link unprocessable
mrns-20231231_def.xml Edgar Link unprocessable
mrns-20231231_pre.xml Edgar Link unprocessable
mrns-20231231_lab.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending